The company is pursuing a focused development strategy with seralutinib as its lead candidate, jointly developed with the Chiesi Group. Gossamer maintains solid cash position (~$180M) but faces regulatory uncertainty following the PROSERA trial outcome, with plans to engage FDA on path forward. The company also has a pipeline including GB004 (IBD), GB001 (eosinophilic asthma), and GB1275 (oncology).
Cyborg Score Rationale
Gossamer Bio exhibits mixed fundamentals: solid liquidity and cash position supporting 1-2 years of runway, but faces critical near-term regulatory hurdle after missing primary PROSERA endpoint. Strong analyst coverage and recent Barclays overweight rating provide some confidence, but binary trial outcome creates significant downside risk. Revenue generation (est. ~$44M) remains pre-commercial.
Top Insights
February 2026 PROSERA Phase 3 results missed primary endpoint (p=0.0320 vs. α=0.025 threshold) but showed +20m benefit in intermediate/high-risk subgroup (p=0.0207)
Strong regional variability with North America showing +25.9m improvement; enrollment paused in SERANATA study pending FDA discussions
Solid balance sheet with ~$180M cash and $200M convertible notes maturing 2027; current market cap ~$561M based on Oct 2025 data
Analyst price targets range $9-10 (341% upside from $2.15 current); Barclays initiated Overweight with $9 PT in early February 2026
Named Competitors
Ambrisentan, Selexipag, Riociguat — Established PAH therapies with proven efficacy and market share
Treprostinil, Selexipag combination — Dominant PAH player with diversified prostanoid portfolio
ACADIA Pharmaceuticals et al. — Rare disease-focused biotech competitors in immunology/inflammation space
Recent Developments
(February 2026) PROSERA Phase 3 topline results announced with 13.3m placebo-adjusted 6MWD improvement, missing primary alpha threshold
(February 2026) Company pausing SERANATA enrollment to evaluate regional placebo response discrepancies and plan FDA engagement
(February 2026) Barclays initiated coverage with Overweight rating and $9 price target
(January 2026) Non-qualified stock option grants approved for non-executive employees under Nasdaq Rule 5635
Open the full interactive Gossamer Bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.